Company press releases

Displaying 1 - 50 of 109 results
Released Company Title Industry Topic
20 Nov 2024
07:00 CET 		ARGENX SE argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies 20103010 Biotechnology Other subject
11 Nov 2024
13:30 CET 		ARGENX SE argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China 20103010 Biotechnology Other subject
05 Nov 2024
07:00 CET 		ARGENX SE argenx to Participate at Upcoming Investor Conferences 20103010 Biotechnology Other subject
31 Oct 2024
07:00 CET 		ARGENX SE argenx Reports Third Quarter 2024 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
24 Oct 2024
07:00 CEST 		ARGENX SE argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 20103010 Biotechnology Other subject
15 Oct 2024
07:00 CEST 		ARGENX SE argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions 20103010 Biotechnology Other subject
19 Sep 2024
07:00 CEST 		ARGENX SE argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
28 Aug 2024
07:00 CEST 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
25 Jul 2024
07:00 CEST 		ARGENX SE argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update 20103010 Biotechnology Other subject
18 Jul 2024
07:00 CEST 		ARGENX SE argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024 20103010 Biotechnology Other subject
16 Jul 2024
06:30 CEST 		ARGENX SE argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China 20103010 Biotechnology Other subject
25 Jun 2024
22:30 CEST 		ARGENX SE argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting 20103010 Biotechnology Other subject
21 Jun 2024
22:50 CEST 		ARGENX SE argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
17 Jun 2024
07:00 CEST 		ARGENX SE argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024 20103010 Biotechnology Other subject
04 Jun 2024
07:00 CEST 		ARGENX SE argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference 20103010 Biotechnology Other subject
09 May 2024
07:00 CEST 		ARGENX SE argenx Reports First Quarter 2024 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
07 May 2024
23:30 CEST 		ARGENX SE argenx announces results of Annual General Meeting of Shareholders 20103010 Biotechnology Other subject
07 May 2024
07:00 CEST 		ARGENX SE argenx to Present at BofA Securities 2024 Health Care Conference 20103010 Biotechnology Other subject
02 May 2024
07:00 CEST 		ARGENX SE argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 20103010 Biotechnology Other subject
16 Apr 2024
07:00 CEST 		ARGENX SE argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease 20103010 Biotechnology Other subject
27 Mar 2024
07:00 CET 		ARGENX SE argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease 20103010 Biotechnology Other subject
26 Mar 2024
21:00 CET 		ARGENX SE argenx Announces Annual General Meeting of Shareholders on May 7, 2024 20103010 Biotechnology Other subject
26 Mar 2024
07:00 CET 		ARGENX SE argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia 20103010 Biotechnology Other subject
07 Mar 2024
22:01 CET 		ARGENX SE argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting 20103010 Biotechnology Other subject
29 Feb 2024
07:00 CET 		ARGENX SE argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update 20103010 Biotechnology Other subject
26 Feb 2024
07:00 CET 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
22 Feb 2024
07:00 CET 		ARGENX SE argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 20103010 Biotechnology Other subject
20 Feb 2024
07:00 CET 		ARGENX SE argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
18 Jan 2024
07:00 CET 		ARGENX SE argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
08 Jan 2024
07:00 CET 		ARGENX SE argenx Highlights 2024 Strategic Priorities 20103010 Biotechnology Other subject
02 Jan 2024
07:00 CET 		ARGENX SE argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Other subject
20 Dec 2023
07:00 CET 		ARGENX SE argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus 20103010 Biotechnology Other subject
28 Nov 2023
07:00 CET 		ARGENX SE argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia 20103010 Biotechnology Other subject
16 Nov 2023
13:40 CET 		ARGENX SE argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
01 Nov 2023
07:00 CET 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
01 Nov 2023
07:00 CET 		ARGENX SE argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions 20103010 Biotechnology Other subject
31 Oct 2023
07:00 CET 		ARGENX SE argenx Reports Third Quarter 2023 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
24 Oct 2023
07:00 CEST 		ARGENX SE argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023 20103010 Biotechnology Other subject
21 Sep 2023
07:00 CEST 		ARGENX SE argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
15 Sep 2023
07:00 CEST 		ARGENX SE argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
30 Aug 2023
07:00 CEST 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
27 Jul 2023
07:00 CEST 		ARGENX SE argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update 20103010 Biotechnology Other subject
24 Jul 2023
22:30 CEST 		ARGENX SE argenx announces closing of global offering 20103010 Biotechnology Other subject
20 Jul 2023
07:00 CEST 		ARGENX SE argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023 20103010 Biotechnology Other subject
19 Jul 2023
23:58 CEST 		ARGENX SE argenx announces full exercise of underwriters’ option to purchase additional ADSs 20103010 Biotechnology Other subject
19 Jul 2023
03:30 CEST 		ARGENX SE argenx raises $1.1 billion in gross proceeds in a global offering 20103010 Biotechnology Other subject
17 Jul 2023
22:01 CEST 		ARGENX SE argenx announces launch of proposed global offering 20103010 Biotechnology Other subject
17 Jul 2023
07:00 CEST 		ARGENX SE argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
30 Jun 2023
15:39 CEST 		ARGENX SE argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China 20103010 Biotechnology Other subject
21 Jun 2023
00:12 CEST 		ARGENX SE argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis 20103010 Biotechnology Other subject